206A
PRISM BioLab Co.,LTD
ＰＲＩＳＭ ＢｉｏＬａｂ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Sep 2024
305,620
Sep 2025
677,330
Operating profit(thousand JPY)
Sep 2024
-782,392
Sep 2025
-774,453
Operating profit margin(%)
Sep 2024
-256
Sep 2025
-114.34
Profit before tax(thousand JPY)
Sep 2024
-1,048,203
Sep 2025
-831,280
Profit(thousand JPY)
Sep 2024
-1,049,514
Sep 2025
-833,700
Total assets(thousand JPY)
Sep 2024
4,528,566
Sep 2025
3,085,692
Cash and cash equivalents(thousand JPY)
Sep 2024
4,392,022
Sep 2025
2,915,572
Cash flows from operating activities(thousand JPY)
Sep 2024
150,144
Sep 2025
-1,468,363
Cash flows from investing activities(thousand JPY)
Sep 2024
-244,187
Sep 2025
-69,013
Cash flows from financing activities(thousand JPY)
Sep 2024
3,370,055
Sep 2025
33,588
Return on equity(-)
Sep 2024
-
Sep 2025
-
Equity ratio(%)
Sep 2024
77.3
Sep 2025
87.6
Earnings per share(JPY per share)
Sep 2024
-33.53
Sep 2025
-22.82
Net assets per share(JPY per share)
Sep 2024
97.41
Sep 2025
73.4
Dividend per share(-)
Sep 2024
-
Sep 2025
-
Payout ratio(-)
Sep 2024
-
Sep 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.